Tuesday, March 18, 2014
AbbVie Hums with Humira
AbbVie (ABBV - $53.10) Chief executive Rick Gonzalez told analysts on the that management expects global Humira sales this year will continue growing at a (low) double-digit pace, excluding the impact of foreign exchange. The pursuit of additional indications currently in late stage clinical trials, such as (inflammation of the eye and the third leading-cause of blindness), is expected to augment growth too.
Humira – like Remicade – is a manufactured monoclonal antibody that treats autoimmune diseases by interfering with (blocking) tumor necrosis factor (TNF), an inflammatory protein over-expressed in a wide range of progressive inflammatory disorders that can result in permanent tissue and joint damage over time.